Analytical detection capabilities of immunoassay-based antiphospholipid antibody tests: Do they matter?

Drug Development Research

Volumn 74, Issue 8, 2013, Pages 575-581

  Lakos, Gabriella ^a  

^a INOVA DIAGNOSTICS INC   (United States)

Author keywords

analytical measuring range; antiphospholipid antibody profile; antiphospholipid syndrome; linearity; new oral anticoagulants; precision; risk stratification

Indexed keywords

ANTICOAGULANT AGENT; AUTOANTIBODY; IMMUNOGLOBULIN G ANTIBODY; PHOSPHOLIPID ANTIBODY;

ANTIBODY DETECTION; ANTIBODY SPECIFICITY; ANTIBODY TITER; ANTICOAGULANT THERAPY; ANTIPHOSPHOLIPID SYNDROME; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOASSAY; IMMUNODIFFUSION; IMMUNOFLUORESCENCE; PREGNANCY COMPLICATION; REVIEW; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 84890552555     PISSN: 02724391     EISSN: 10982299     Source Type: Journal    
DOI: 10.1002/ddr.21117     Document Type: Review

References (42)

1. Andreoli L, Tincani A,. 2012. Beyond the "syndrome": antiphospholipid antibodies asrisk factors. Arthritis Rheum 64: 342-345.
2. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G, American College of Chest Physicians. 2008. Pharmacology and management of the vitamin K antagonists: American college of chest physicians evidence-based clinical practice guidelines. Chest 133: 160S-198S.
3. Armbruster DA, Pry T,. 2008. Limit of blank, limit of detection and limit of quantitation. Clin Biochem Rev 29: S49-S52.
4. Bakshi J, Stevens R,. 2013. Rituximab therapy for recurrent thromboembolic disease in antiphospholipid syndrome. Lupus 22: 865-867.
5. Bertolaccini ML, Sciascia S, Murru V, Garcia-Fernandez C, Sanna G, Khamashta MA,. 2013. Prevalence of antibodies to prothrombin in solid phase (aPT) and to phosphatidylserine-prothrombin complex (aPS/PT) in patients with and without lupus anticoagulant. Thromb Haemost 109: 207-213.
6. de Laat B, Derksen RH, Urbanus RT, de Groot PG,. 2005. IgG antibodies that recognize epitope Gly40-Arg43 in domain I of beta 2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis. Blood 105: 1540-1545.
7. de Laat B, Pengo V, Pabinger I, Musial J, Voskuyl AE, Bultink IE, Ruffatti A, Rozman B, Kveder T, de Moerloose P, et al. 2009. The association between circulating antibodies against domain I of beta2-glycoprotein I and thrombosis: an international multicenter study. J Thromb Haemost 7: 1767-1773.
8. Devreese KM, Van Hoecke F,. 2011. Anticardiolipin and anti-β2glycoprotein-I antibody cut-off values in the diagnosis of antiphospholipid syndrome: more than calculating the in-house 99th percentiles, even for new automated assays. Thromb Res 128: 598-600.
9. Egerer K, Roggenbuck D, Büttner T, Lehmann B, Kohn A, von Landenberg P, Hiemann R, Feist E, Burmester GR, Dörner T,. 2011. Single-step autoantibody profiling in antiphospholipid syndrome using a multi-line dot assay. Arthritis Res Ther 13: R118.
10. Erre GL, Pardini S, Faedda R, Passiu G,. 2008. Effect of rituximab on clinical and laboratory features of antiphospholipid syndrome: a case report and a review of literature. Lupus 17: 50-55.
11. Fawole A, Daw HA, Crowther MA,. 2013. Practical management of bleeding due to the anticoagulants dabigatran, rivaroxaban, and apixaban. Cleve Clin J Med 80: 443-451.
12. Galli M, Luciani D, Bertolini G, Barbui T,. 2003. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 101: 1827-1832.
13. Ghanny S, Crowther M,. 2013. Treatment with novel oral anticoagulants: indications, efficacy and risks. Curr Opin Hematol 5: 430-436.
14. Ginsburg KS, Liang MH, Newcomer L, Goldhaber SZ, Schur PH, Hennekens CH, Stampfer MJ,. 1992. Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis. Ann Intern Med 117: 997-1002.
15. Khattri S, Zandman-Goddard G, Peeva E,. 2012. B-cell directed therapies in antiphospholipid antibody syndrome-new directions based on murine and human data. Autoimmun Rev 11: 717-722.
16. King CS, Holley AB, Moores LK,. 2013. Moving toward a more ideal anticoagulant: the oral direct thrombin and factor Xa inhibitors. Chest 143: 1106-1116.
17. Lakos G, Favaloro EJ, Harris EN, Meroni PL, Tincani A, Wong RC, Pierangeli SS,. 2012. International consensus guidelines on anticardiolipin and anti-β2-glycoprotein I testing: report from the 13th international congress on antiphospholipid antibodies. Arthritis Rheum 64: 1-10.
18. Levy JH, Faraoni D, Spring JL, Douketis JD, Samama CM,. 2013. Managing new oral anticoagulants in the perioperative and intensive care unit setting. Anesthesiology 118: 1466-1474.
19. McMillin GA, Vazquez SR, Pendleton RC,. 2011. Current challenges in personalizing warfarin therapy. Expert Rev Clin Pharmacol 4: 349-362.
20. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, Derksen RH, de Groot PG, Koike T, Meroni PL, et al. 2006. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4: 295-306.
21. Neville C, Rauch J, Kassis J, Chang ER, Joseph L, Le Comte M, Fortin PR,. 2003. Thromboembolic risk in patients with high titre anticardiolipin and multiple antiphospholipid antibodies. Thromb Haemost 90: 108-115.
22. Otomo K, Atsumi T, Amengual O, Fujieda Y, Kato M, Oku K, Horita T, Yasuda S, Koike T,. 2012. Efficacy of the antiphospholipid score for the diagnosis ofantiphospholipid syndrome and its predictive value for thrombotic events. Arthritis Rheum 64: 504-512.
23. Pengo V, Biasiolo A, Pegoraro C, Cucchini U, Noventa F, Iliceto S,. 2005. Antibody profiles for the diagnosis of antiphospholipid syndrome. Thromb Haemost 93: 1147-1152.
24. Pengo V, Ruffatti A, Legnani C, Testa S, Fierro T, Marongiu F, de Micheli V, Gresele P, Tonello M, Ghirarduzzi A, et al. 2011. Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study. Blood 118: 4714-4718.
25. Pengo V, Ruffatti A, Del Ross T, Tonello M, Cuffaro S, Hoxha A, Banzato A, Bison E, Denas G, Bracco A, et al. 2013. Confirmation of the initial antiphospholipid antibody positivity depends on antiphospholipid antibody profile. J Thromb Haemost 11: 1527-1531.
26. Persijn L, Decavele AS, Schouwers S, Devreese K,. 2011. Evaluation of a new set ofautomated chemiluminescense assays for anticardiolipin andanti-beta2-glycoprotein I antibodies in the laboratory diagnosis of the antiphospholipid syndrome. Thromb Res 128: 565-569.
27. Pierangeli SS, Chen PP, Raschi E, Scurati S, Grossi C, Borghi MO, Palomo I, Harris EN, Meroni PL,. 2008. Antiphospholipid antibodies and the antiphospholipid syndrome: pathogenic mechanisms. Semin Thromb Hemost 34: 236-250.
28. Pierangeli SS, de Groot PG, Dlott J, Favaloro E, Harris EN, Lakos G, Ortel T, Meroni PL, Otomo K, Pengo V, et al. 2011. "Criteria" aPL tests: report of a task force and preconference workshop at the 13th international congress on antiphospholipid antibodies, Galveston, Texas. Lupus 20: 182-190.
29. Poulsen BK, Grove EL, Husted SE,. 2012. New oral anticoagulants: a review of the literature with particular emphasis on patients with impaired renal function. Drugs 72: 1739-1753.
30. Prandoni P, Dalla Valle F, Piovella C, Tormene D, Pesavento R,. 2013. New anticoagulants for the treatment of venous thromboembolism. Minerva Med 104: 131-139.
31. Roubey RA,. 2010. Risky business: the interpretation, use, and abuse of antiphospholipid antibody tests in clinical practice. Lupus 19: 440-445.
32. Ruffatti A, Olivieri S, Tonello M, Bortolati M, Bison E, Salvan E, Facchinetti M, Pengo V,. 2008. Influence of different IgG anticardiolipin antibody cut-off values on antiphospholipid syndrome classification. J Thromb Haemost 6: 1693-1696.
33. Ruffatti A, Tonello M, Visentin MS, Bontadi A, Hoxha A, de Carolis S, Botta A, Salvi S, Nuzzo M, Rovere-Querini P, et al. 2011. Risk factors for pregnancy failure in patients withanti-phospholipid syndrome treated with conventional therapies: a multicentre,case-control study. Rheumatology (Oxford) 50: 1684-1689.
34. Sciascia S, Murru V, Sanna G, Roccatello D, Khamashta MA, Bertolaccini ML,. 2012. Clinical accuracy for diagnosis of antiphospholipid syndrome in systemic lupus erythematosus: evaluation of 23 possible combinations of antiphospholipid antibody specificities. J Thromb Haemost 10: 2512-2518.
35. Simchen MJ, Dulitzki M, Rofe G, Shani H, Langevitz P, Schiff E, Pauzner R,. 2011. High positive antibody titers and adverse pregnancy outcome in women with antiphospholipid syndrome. Acta Obstet Gynecol Scand 90: 1428-1433.
36. Tarr T, Lakos G, Bhattoa HP, Shoenfeld Y, Szegedi G, Kiss E,. 2007. Analysis of risk factors for the development of thrombotic complications in antiphospholipidantibody positive lupus patients. Lupus 16: 39-45.
37. Torres JL, Ridker PM,. 2003. Clinical use of high sensitivity C-reactive protein for the prediction of adverse cardiovascular events. Curr Opin Cardiol 18: 471-478.
38. Turiel M, Sarzi-Puttini P, Peretti R, Rossi E, Atzeni F, Parsons W, Doria A,. 2005. Thrombotic risk factors in primary antiphospholipid syndrome: a 5-year prospective study. Stroke 36: 1490-1494.
39. Van Hoecke F, Persijn L, Decavele AS, Devreese K,. 2012. Performance of two new,automated chemiluminescence assay panels for anticardiolipin andanti-beta2-glycoprotein I antibodies in the laboratory diagnosis of theantiphospholipid syndrome. Int J Lab Hematol. 34: 410-416.
40. Vikerfors A, Johansson AB, Gustafsson JT, Jönsen A, Leonard D, Zickert A, Nordmark G, Sturfelt G, Bengtsson A, Rönnblom L, et al. 2013. Clinical manifestations and anti-phospholipid antibodies in 712 patients with systemic lupus erythematosus: evaluation of two diagnostic assays. Rheumatology (Oxford) 52: 501-509.
41. Villalta D, Alessio MG, Tampoia M, Da Re A, Stella S, Da Re M, Tozzoli R, Bizzaro N,. 2009. Accuracy of the first fully automated method for anti-cardiolipin and anti-beta2 glycoprotein I antibody detection for the diagnosis of antiphospholipid syndrome. Ann N Y Acad Sci 1173: 21-27.
42. Windgassen EB, Funtowicz L, Lunsford TN, Harris LA, Mulvagh SL,. 2011. C-reactive protein and high-sensitivity C-reactive protein: an update for clinicians. Postgrad Med 123: 114-1149.